Jun 25, 2026 04:31PM

Jun 25, 2026 04:30PM

Mar 9, 2026 07:00AM

Aug 4, 2025 04:05PM

Jun 16, 2025 04:31PM

Jun 16, 2025 04:30PM

Apr 3, 2025 07:00AM Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle B

Dec 23, 2024 07:05AM

Dec 23, 2024 07:00AM

Nov 6, 2024 07:00AM

Sep 27, 2024 05:15PM

Sep 11, 2024 07:00AM

Oct 5, 2023 07:00AM

Jun 22, 2020 04:34PM Castle Biosciences Inc. (CSTL) Announces Proposed 1.5M Underwritten Public Offering of Common Stock

Jun 22, 2020 04:33PM

Jun 22, 2020 04:22PM

Mar 10, 2020 04:05PM

Mar 5, 2020 07:00AM

Jan 20, 2020 07:00AM

Jan 9, 2020 05:00PM

Dec 30, 2019 07:01AM Castle Biosciences Inc. (CSTL) Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology

Dec 30, 2019 07:00AM

Nov 25, 2019 07:00AM

Nov 11, 2019 04:05PM

Oct 31, 2019 07:00AM

Oct 29, 2019 07:00AM

Oct 28, 2019 07:00AM

Oct 18, 2019 07:00AM Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node

Sep 19, 2019 07:00AM

Sep 3, 2019 04:05PM

Jul 19, 2019 05:09PM

Jul 15, 2019 06:18AM

67,219 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All